Corujo M, Badlani G H
Department of Urology, Long Island Jewish Medical Center, New Hyde Park, New York 11042, USA.
J Endourol. 1998 Aug;12(4):385-8. doi: 10.1089/end.1998.12.385.
The UroLume endoprosthesis has been used for recurrent bulbar urethral strictures, benign prostatic hyperplasia, and detrusor-external sphincter dyssynergia. Complications of the UroLume have been described by the North American Multicenter Trial as migration, encrustation, hyperplastic tissue growth, in addition to pain and irritative voiding symptoms. Generally, complications have been minimal, and few of the stents required removal. Patients with bulbar strictures were felt to be at relatively greater risk of hyperplastic tissue reaction if their stricture was secondary to trauma or if they had a prior urethroplasty. On the other hand, patients with benign prostatic hyperplasia were at risk of developing complications if they had median lobe enlargement or a short (<2.5 cm) prostatic urethra. We describe two cases in which off-label compassionate use of UroLumes in the anterior urethra and in an irradiated urethra led to adverse reactions such as stent separation, poor epithelialization, hyperplastic tissue growth, encrustation, or obstruction necessitating removal.
UroLume 内支架已用于复发性球部尿道狭窄、良性前列腺增生以及逼尿肌-外括约肌协同失调。北美多中心试验描述了 UroLume 的并发症，包括移位、结壳、增生性组织生长，以及疼痛和刺激性排尿症状。一般来说，并发症较少，很少有支架需要取出。如果球部狭窄继发于创伤或患者曾接受过尿道成形术，则认为这些患者发生增生性组织反应的风险相对较高。另一方面，如果患有良性前列腺增生的患者中叶增大或前列腺尿道较短（<2.5 cm），则有发生并发症的风险。我们描述了两例病例，其中在未按标签说明的情况下，出于同情在尿道前部和放疗后的尿道中使用 UroLume 导致了诸如支架分离、上皮化不良、增生性组织生长、结壳或梗阻等不良反应，需要取出支架。
